plexiform neurofibroma (Cancer)
Information
- Disease name
- plexiform neurofibroma
- Disease ID
- DOID:5151
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04954001 | Active, not recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | March 26, 2021 | March 30, 2025 |
| NCT00924196 | Active, not recruiting | Natural History Study of Patients With Neurofibromatosis Type I | February 25, 2008 | ||
| NCT03231306 | Active, not recruiting | Phase 2 | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | November 28, 2017 | December 31, 2026 |
| NCT03363217 | Active, not recruiting | Phase 2 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | August 16, 2018 | March 1, 2027 |
| NCT03820778 | Active, not recruiting | N/A | Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | July 12, 2018 | August 1, 2022 |
| NCT03962543 | Active, not recruiting | Phase 2 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | September 29, 2019 | May 23, 2025 |
| NCT00396019 | Completed | Phase 2 | Study of PEG-Intron for Plexiform Neurofibromas | December 2006 | April 2014 |
| NCT00727233 | Completed | Phase 1 | Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | July 8, 2008 | June 16, 2011 |
| NCT03326388 | Completed | Phase 1/Phase 2 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours | September 26, 2019 | February 14, 2024 |
| NCT01412892 | Completed | Phase 2 | Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | April 2011 | October 2014 |
| NCT01800032 | Completed | PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) | January 16, 2013 | December 5, 2019 | |
| NCT06188741 | Not yet recruiting | Phase 2 | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | August 1, 2024 | August 1, 2031 |
| NCT06379230 | Recruiting | A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | January 1, 2019 | February 28, 2025 | |
| NCT05913037 | Recruiting | Phase 3 | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | June 20, 2023 | June 30, 2026 |
| NCT06104488 | Recruiting | Phase 1 | A Study of Avutometinib for People With Solid Tumor Cancers | October 20, 2023 | October 20, 2029 |
| NCT00326872 | Terminated | Phase 2 | AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | May 2006 | May 31, 2016 |
- Disase is a (Disease Ontology)
- DOID:962
- Cross Reference ID (Disease Ontology)
- ICDO:9550/0
- Cross Reference ID (Disease Ontology)
- MESH:D018318
- Cross Reference ID (Disease Ontology)
- NCI:C3797
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:41252002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206728
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0009732